Legend Biotech Corporation (LEGN)

Market Cap	8.26B
Revenue (ttm)	285.14M
Net Income (ttm)	-518.25M
Shares Out	181.91M
EPS (ttm)	-2.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	689,465
Open	46.33
Previous Close	45.93
Day's Range	45.24 - 46.81
52-Week Range	42.08 - 77.32
Beta	0.01
Analysts	Strong Buy
Price Target	84.50 (+86.08%)
Earnings Date	May 13, 2024

About LEGN

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2020
• Employees: 1,826
• Stock Exchange: NASDAQ
• Ticker Symbol: LEGN

Financial Performance

In 2023, Legend Biotech's revenue was $285.14 million, an increase of 143.70% compared to the previous year's $117.01 million. Losses were -$518.25 million, 16.1% more than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for LEGN stock is "Strong Buy." The 12-month stock price forecast is $84.5, which is an increase of 86.08% from the latest price.

Price Target

$84.5

(86.08% upside)

Analyst Consensus: Strong Buy